1. Home
  2. JBI vs ANL Comparison

JBI vs ANL Comparison

Compare JBI & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Janus International Group Inc.

JBI

Janus International Group Inc.

HOLD

Current Price

$5.31

Market Cap

728.3M

Sector

Industrials

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$12.66

Market Cap

611.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
JBI
ANL
Founded
2002
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Building Products
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
728.3M
611.1M
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
JBI
ANL
Price
$5.31
$12.66
Analyst Decision
Hold
Strong Buy
Analyst Count
3
1
Target Price
$9.17
$20.00
AVG Volume (30 Days)
1.2M
253.4K
Earning Date
05-12-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$9.36
$36.02
Revenue Next Year
$3.16
N/A
P/E Ratio
$12.96
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.26
$0.88
52 Week High
$10.80
$17.25

Technical Indicators

Market Signals
Indicator
JBI
ANL
Relative Strength Index (RSI) 49.52 54.70
Support Level $4.89 $11.86
Resistance Level $5.50 $12.24
Average True Range (ATR) 0.15 1.14
MACD -0.01 0.31
Stochastic Oscillator 58.47 68.40

Price Performance

Historical Comparison
JBI
ANL

About JBI Janus International Group Inc.

Janus International Group Inc is a manufacturer and supplier of turnkey solutions for self-storage, commercial, and industrial building Solutions. It provides products that include roll-up and swing doors, hallway systems, relocatable storage MASS (Moveable Additional Storage Structures) units, and technologies for automating facility and door operation. It is operated through two geographic regions; Janus North America and Janus International. The Janus International segment is comprised of a subsidiary whose production and sales are largely in Europe and Australia. The Janus North America segment is comprised of all the other entities.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: